Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

被引：1
|
作者：
Moik, F. [1 ,2 ]
Riedl, J. M. [2 ]
Ay, C. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Haematol & Haemostaseol, Vienna, Austria
[2] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期
关键词：
D O I：
10.1016/j.annonc.2023.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [21] CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
    Shu, Catherine A.
    Goto, Koichi
    Cho, Byoung Chul
    Griesinger, Frank
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Xie, John
    Chen, Jun
    Mahoney, Janine
    Thayu, Meena
    Knoblauch, Roland Elmar
    Trani, Leonardo
    Bauml, Joshua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
    Riess, Jonathan W.
    Krailo, Mark D.
    Padda, Sukhmani Kaur
    Groshen, Susan G.
    Wakelee, Heather A.
    Reckamp, Karen L.
    Koczywas, Marianna
    Piotrowska, Zofia
    Steuer, Conor Ernst
    Kim, Chul
    Paweletz, Cloud P.
    Sholl, Lynette M.
    Heavey, Grace
    Kolesar, Jill
    Moscow, Jeffrey
    Janne, Pasi A.
    Lara, Primo
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
    Hata, Akito
    Katakami, Nobuyuki
    Takase, Naoto
    Kibata, Kayoko
    Yamanaka, Yuta
    Tamiya, Motohiro
    Mori, Masahide
    Kijima, Takashi
    Morita, Satoshi
    Sakai, Kazuko
    Nishio, Kazuto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
    Cho, Byoung Chul
    Wang, Yongsheng
    Felip, Enriqueta
    Cui, Jiuwei
    Spira, Alexander I.
    Neal, Joel W.
    Baik, Christina
    Marmarelis, Melina Elpi
    Ichihara, Eiki
    Lee, Jong-Seok
    Lee, Se-Hoon
    Yang, James Chih-Hsin
    Michels, Sebastian Yves Friedrich
    Anastasiou, Zacharias
    Curtin, Joshua C.
    Lyu, Xuesong
    Leconte, Isabelle
    Trani, Leonardo
    Baig, Mahadi
    Tomasini, Pascale
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
    Zhang, Chao
    Sun, Yu-Xuan
    Yi, Ding-Cheng
    Jiang, Ben-Yuan
    Yan, Li-Xu
    Liu, Ze-Dao
    Peng, Li-Shan
    Zhang, Wen-Jie
    Sun, Hao
    Chen, Zhi-Yong
    Wang, Dan-Hua
    Peng, Di
    Chen, Song-An
    Li, Si-Qi
    Zhang, Ze
    Tan, Xiao-Yue
    Yang, Jie
    Zhao, Zhang-Yi
    Zhang, Wan-Ting
    Su, Jian
    Li, Yang-Si
    Liao, Ri-Qiang
    Dong, Song
    Xu, Chong-Rui
    Zhou, Qing
    Yang, Xue-Ning
    Wu, Yi-Long
    Zhang, Ze-Min
    Zhong, Wen-Zhao
    CELL REPORTS MEDICINE, 2024, 5 (07)
  • [26] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Chang, Allison E. B.
    Piper-Vallillo, Andrew J.
    Mak, Raymond H.
    Lanuti, Michael
    Muzikansky, Alona
    Rotow, Julia
    Jaenne, Pasi A.
    Mino-Kenudson, Mari
    Swanson, Scott
    Wright, Cameron D.
    Kozono, David
    Marcoux, Paul
    Piotrowska, Zofia
    Sequist, Lecia, V
    Willers, Henning
    ONCOLOGIST, 2024, 29 (07): : 609 - 618
  • [29] Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinibresistant, EGFR-mutant non-small cell lung cancer (NSCLC).
    Elamin, Yasir Y.
    Negrao, Marcelo Vailati
    Fossella, Frank V.
    Byers, Lauren Averett
    Zhang, Jianjun
    Gay, Carl Michael
    Tu, Janet Chen
    Pozadzides, Jenny Vu
    Tran, Hai T.
    Lu, Charles
    Feng, Lei
    Spelman, Amy R.
    Blumenschein, George R.
    Tsao, Anne S.
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
    Zhao, Hongyun
    Yao, Wenxiu
    Min, Xuhong
    Gu, Kangsheng
    Yu, Guohua
    Zhang, Zhonghan
    Cui, Jiuwei
    Miao, Liyun
    Zhang, Li
    Yuan, Xia
    Fang, Yong
    Fu, Xiuhua
    Hu, Chengping
    Zhu, Xiaoli
    Fan, Yun
    Yu, Qitao
    Wu, Gang
    Jiang, Ou
    Du, Xiuping
    Liu, Jiwei
    Gu, Wei
    Hou, Zhiguo
    Wang, Quanren
    Zheng, Rongrong
    Zhou, Xianfeng
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1533 - 1546
12345